Longitudinal algorithm may detect ovarian cancer earlier

December 21, 2012
Longitudinal algorithm may detect ovarian cancer earlier
Compared with a single-threshold rule, a parametric empirical Bayes longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

(HealthDay)—Compared with a single-threshold (ST) rule, a parametric empirical Bayes (PEB) longitudinal screening algorithm can identify ovarian cancer earlier and at a lower concentration of CA125, according to research published online Dec. 17 in the Journal of Clinical Oncology.

Charles W. Drescher, M.D., of the Fred Hutchinson Cancer Research Center in Seattle, and colleagues compared an ST rule with a PEB longitudinal screening algorithm in a retrospective evaluation of preclinical CA125 values measured annually in 44 participants with incident from the Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial.

The researchers found that, in many cases, ovarian cancer was detected earlier using the PEB algorithm, compared to using an ST rule. At a specificity of 99 percent, corresponding to an ST rule CA125 cut-off of ≥35 U/mL used in the PLCO trial, use of the PEB algorithm would have identified 20 percent of cases earlier. The PEB indicated abnormal CA125 values among these cases 10 months earlier and at a lower CA125 concentration (42 percent lower; 20 U/mL) than an ST rule cut-off. As the specificity of screening was reduced, there was an increase in the proportion of cases detected earlier by PEB.

"Our results demonstrated that, for ovarian by using , the PEB longitudinal algorithm detected ovarian cancer earlier than an ST rule in a statistically significant and meaningful proportion of cases," the authors write. "This observation was consistent across a range of specificities relevant for a first-line test in a multimodal ."

Explore further: Symptom screening plus a simple blood test improves early detection of ovarian cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Assessing lead time of selected ovarian cancer biomarkers

December 31, 2009

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal ...

FDA clears biomarker test for ovarian cancer

September 6, 2011

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

Recommended for you

Molecularly shutting down cancer cachexia

August 30, 2016

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Radiologists detect breast cancer in 'blink of an eye'

August 29, 2016

A new study by investigators at Brigham and Women's Hospital in collaboration with researchers at the University of York and Leeds in the UK and MD Andersen Cancer Center in Texas puts to the test anecdotes about experienced ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.